RPG Life Sciences is poised to enter India's rapidly expanding GLP-1 drug market in October, a strategic move supported by recent significant investments in its Active Pharmaceutical Ingredient (API) business. The company has finalized two API acquisitions totaling ₹215 crore, substantially boosting its manufacturing capabilities and market reach.
Strategic Entry into the GLP-1 Market
Managing Director Ashok Nair confirmed that RPG Life Sciences is preparing for the October launch of its GLP-1 product, developed in collaboration with a research innovator. Nair emphasized the considerable potential within the GLP-1 segment, especially given the company's established presence in niche therapeutic areas.
Industry projections suggest India's GLP-1 market could grow to approximately ₹4,000 crore within the next three to four years. RPG Life Sciences aims to secure a notable share of this burgeoning market through its specialized portfolio.
API Business Expansion Through Key Acquisitions
The company's foray into the GLP-1 space coincides with a robust expansion of its API division. Within a span of five weeks, RPG Life Sciences invested ₹215 crore to acquire Actis Generics for ₹85 crore and subsequently Raghava Life Sciences. These acquisitions have dramatically increased its API manufacturing capacity from 110 KL to 505 KL.
The impact extends beyond mere capacity:
- API customer base grew from 123 to over 250.
- Product portfolio expanded from 14 to 45.
- R&D pipeline increased from 12 to 28 products.
- The API workforce more than doubled, from 217 to over 500 employees.
These strategic moves have transformed RPG Life Sciences from a purely API-focused entity into a backward-integrated API and advanced intermediates provider.
Future Investment and Niche Focus
To support its ambitious growth trajectory, RPG Life Sciences initially established a dedicated API division, "RPG Active Pharma," and secured ₹243 crore from a healthcare-focused private equity investor. This created a committed investment pool of approximately ₹700 crore for the API business.
Looking ahead, the company plans to deploy an additional ₹500-700 crore over the next 12 months. This investment will target further acquisitions aimed at strengthening its manufacturing footprint, enhancing its product portfolio, and expanding technical capabilities. A key focus is acquiring a large manufacturing site, ideally one with USFDA approvals, to complement existing operations.
RPG Life Sciences intends to concentrate on niche APIs that involve complex chemistry and multi-step synthesis. This strategy targets products with higher technical entry barriers, fostering stronger customer loyalty and reducing susceptibility to price erosion, as explained by Ashok Nair.
Current manufacturing facilities show varied utilization rates: Navi Mumbai at around 60%, Actis near full capacity, and Raghava at approximately 20%. The company anticipates Raghava alone could generate around ₹200 crore in revenue once its utilization reaches 70-80%, with an overall target of 75-80% utilization across all three API manufacturing sites post-integration.